Posted: Jul 21, 2021 1:11 PM
The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
With 162 million American adults being fully vaccinated, America’s successes against COVID-19 provide hope that the U.S. Food and Drug Administration (FDA) can step up its game. And recently, it looks like the agency is starting to do just that by approving more treatments for deadly diseases. In June, the FDA used its accelerated approval (AA) pathway to allow Alzheimer’s patients access to a new drug designed to slow memory loss. But regulatory progress has been uneven. The agency is still far too slow in approving medicines and therapies to treat, or at least slow down the symptoms, devastating illnesses such as amyotrophic lateral sclerosis (ALS). America’s drug regulator must allow access to novel therapies that can address life-threatening diseases and illnesses.
Understanding how the FDA approves anything can be mind-numbingly confusing. In December of 2020, the agency approved Pfizer and Moderna’s COVID-19 vaccines for emergency use authorization (EUA), which provides “timely and practical medical treatment or prevention